Torex renews buyback program for 7,176,403 shares and extends trading to New York
Key Facts
Torex Resources renewed its normal course issuer bid, authorizing it to repurchase up to 7,176,403 shares, or about 10% of its public float as of Nov. 11, 2026, according to a filing by the company with the U.S. Securities and Exchange Commission. The move follows the start of trading in the company’s shares on the New York Stock Exchange under the ticker TXR at the market open on Nov. 17. The new program begins on Nov. 23, 2026, and runs through Nov. 22, 2027. The filing sets a ceiling on potential purchases but does not require the company to use the full amount or buy any shares. The company said buyback decisions will depend on market conditions, the share price and other opportunities to invest capital in growth.
The New York listing is secondary, as Torex retains its primary listing on the Toronto Stock Exchange, and the move involved no new share issuance or capital raising. The company said in an earlier filing that the secondary listing was expected to broaden and increase its access to capital markets, improve trading liquidity and expand research coverage. The listing thus adds a U.S. venue for trading the shares while the company retains its primary Canadian listing. Trading began two days before the announcement renewing the buyback program. This sequence distinguishes the start of trading in New York from the renewal of the bid, two separate announcements in November.
The program’s maximum was based on the public float, not total issued and outstanding shares. Total shares stood at 90,251,272 on Nov. 11, 2026, compared with a public float of 71,764,036 shares on the same date. The public float is the basis for the 10% figure announced by the company, while the specified purchase cap is 7,176,403 shares. The filing said purchases could be made on the open market through the Toronto Stock Exchange, the New York Stock Exchange or alternative trading systems in Canada and the United States. The company intends to fund any purchases from available working capital and retains the right to suspend them at any time.
The previous bid offers an indication of the gap between the authorized limit and purchases actually made. In the third quarter of 2026, the company repurchased 1,755,843 shares for $83.8 million, at an average price of $47.74 per share. From the start of the year through Sept. 30, total repurchases reached 4,888,626 shares valued at $238.8 million. Third-quarter results showed revenue of $555 million and free cash flow of $150 million during the quarter, bringing the year-to-date total to $402 million. Net income was $155.2 million in the third quarter of 2026, compared with $114.4 million in the same period of 2025; the company attributed the increase mainly to higher realized prices and gold-equivalent sales.
Torex, by its own description in the company filing, produces, develops and explores for gold, copper and silver, and its main Morelos complex is in Mexico’s Guerrero state. The company also lists the Medicine Springs project in Nevada among its early-stage exploration projects. Third-quarter 2026 production was 131,900 ounces of gold equivalent, and the gold recovery rate rose to 88.2% from 85.4% in the previous quarter. The company said higher production reflected higher ore grades and improved recovery. It plans to begin a plant debottlenecking project in 2027, with benefits potentially emerging late in the year, and the project could raise processing rates by 10% to 15% with relatively modest capital investment.
The company said an evaluation of the feasibility of a further plant expansion will be guided by drilling along the San Miguel corridor throughout 2027, with a decision targeted for early 2028. This timeline puts the expansion decision after the drilling period that will inform it, according to the third-quarter results filing. The renewed buyback program runs from Nov. 23, 2026, following the start of trading in New York on Nov. 17 and the announcement renewing the program on Nov. 19. Potential purchases remain subject to the company’s discretion, market conditions, the share price and capital investment opportunities. The program’s specified cap does not require the company to purchase the full authorized amount.